相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial
Gilles Salles et al.
LANCET (2011)
High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years
Emmanuel Gyan et al.
BLOOD (2009)
Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance
Panayiotis D. Ziakas et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project
Massimo Federico et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Rituximab Maintenance for the Treatment of Patients With Follicular Lymphoma: Systematic Review and Meta-analysis of Randomized Trials
Liat Vidal et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab
Issa F. Khouri et al.
BLOOD (2008)
Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage
Marco Ladetto et al.
BLOOD (2008)
Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study
Gilles Salles et al.
BLOOD (2008)
Phase III Trial of Consolidation Therapy With Yttrium-90-Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma
Franck Morschhauser et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma:: A GELA study
Catherine Sebban et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma:: An East German Study Group hematology and oncology study
Michael Herold et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: A systematic review and meta-analysis
Holger Schulz et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Revised response criteria for malignant lymphoma
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Results of a national consensus workshop:: therapeutic algorithm in patients with follicular lymphoma -: role of radioimmunotherapy
M. Dreyling et al.
ANNALS OF HEMATOLOGY (2007)
Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA)
Catherine Sebban et al.
BLOOD (2006)
The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome
Christian Buske et al.
BLOOD (2006)
Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone:: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
W Hiddemann et al.
BLOOD (2005)
Quantitative PCR of bone marrow BCL2/IgH+ cells at diagnosis predicts treatment response and long-term outcome in follicular non-Hodgkin lymphoma
A Rambaldi et al.
BLOOD (2005)
Meta-analysis to evaluate the role of interferon in follicular lymphoma
AZS Rohatiner et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
131I-tositumomab therapy as initial treatment for follicular lymphoma
MS Kaminski et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Stage I and II follicular non-Hodgkin's lymphoma: Long-term follow-up of no initial therapy
R Advani et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Follicular lymphoma international prognostic index
P Solal-Céligny et al.
BLOOD (2004)
Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells
SS Dave et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group
G Lenz et al.
BLOOD (2004)
Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma
K van Besien et al.
BLOOD (2003)
Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial
KM Ardeshna et al.
LANCET (2003)
High-dose, therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: Results from the randomized European CUP trial
HC Schouten et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma:: 2 types of follicular lymphoma grade 3
G Ott et al.
BLOOD (2002)
分享论文
